Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
---|
Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
---|
Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
---|
In the preceding three months, 4 analysts have released ratings for Absci (NASDAQ:ABSI), presenting a wide array of perspectives from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
---|---|---|---|---|---|
Total Ratings | 2 | 2 | 0 | 0 | 0 |
Last 30D | 1 | 0 | 0 | 0 | 0 |
1M Ago | 0 | 1 | 0 | 0 | 0 |
2M Ago | 1 | 0 | 0 | 0 | 0 |
3M Ago | 0 | 1 | 0 | 0 | 0 |
The 12-month price targets, analyzed by analysts, offer insights with an average target of $7.25, a high estimate of $9.00, and a low estimate of $5.00. Observing a 81.25% increase, the current average has risen from the previous average price target of $4.00.
A clear picture of Absci's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
---|---|---|---|---|---|
Robyn Karnauskas | Truist Securities | Announces | Buy | $9.00 | - |
Scott Schoenhaus | Keybanc | Raises | Overweight | $8.00 | $5.00 |
Swayampakula Ramakanth | HC Wainwright & Co. | Raises | Buy | $7.00 | $4.00 |
Scott Schoenhaus | Keybanc | Raises | Overweight | $5.00 | $3.00 |
To gain a panoramic view of Absci's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
Stay up to date on Absci analyst ratings.
If you are interested in following small-cap stock news and performance you can start by tracking it here.
Absci Corp is the Artificial intelligence powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. It enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process.
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: Absci's revenue growth over a period of 3 months has faced challenges. As of 30 September, 2023, the company experienced a revenue decline of approximately -68.59%. This indicates a decrease in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Absci's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of -2956.18%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Absci's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -10.68% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Absci's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -8.97% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: With a below-average debt-to-equity ratio of 0.09, Absci adopts a prudent financial strategy, indicating a balanced approach to debt management.
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Posted In: ABSI